Clinical Trials
5 trialsNCT00039780 2022-07-13
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT01775449 2017-07-11
NEUROXAPOL
University Hospital, Clermont-Ferrand
Phase 3 Completed
NCT00305188 2016-05-04
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Sanofi
Phase 3 Completed
NCT00746694 2015-08-27
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
Merck Sharp & Dohme LLC
Completed
NCT00272051 2006-09-13
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
Sanofi
Phase 3 Completed